Orexigen Therapeutics, Inc. (OREX) Posts Mixed Q1 Results
Tweet
Share
E-mailGet Alerts OREX Hot Sheet
Join SI Premium – FREE
Orexigen Therapeutics, Inc. (NASDAQ: OREX) reported Q1 EPS of ($0.24), $0.03 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $1.83 million versus the consensus estimate of $640 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
- Taylor Devices (TAYD) Misses Q4 EPS by 31c
- VNET Group (VNET) Misses Q2 EPS by 164c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
